Sex | | | 0.365 |
Males | 12 (55.5) | 9 (40.9) | |
Females | 10 (45.5) | 13 (59.1) | |
Age years | 63.1±13.5 | 66.8±8.4 | 0.272 |
Ex-smokers | 7 (31.8) | 9 (40.9) | 0.531 |
BMI kg·m−2 | 24.3±3.5 | 25.7±4.2 | 0.238 |
Exacerbations in the past year¶ | 2 (1–3.25) | 1 (0.75–2.25) | 0.189 |
Aetiology# | | | 0.368 |
Post-infective | 9 (40.9) | 4 (18.2) | |
Idiopathic | 7 (31.8) | 10 (45.5) | |
Immune deficiency | 2 (9.1) | 1 (4.5) | |
Gastro-oesophageal reflux | 2 (9.1) | 5 (22.7) | |
Other | 2 (9.1) | 2 (9.1) | |
24-h sputum volume mL | 20 (15–40) | 15 (15–20) | 0.061 |
Sputum colour# | | | 0.074 |
Mucous | 2 (9.1) | 7 (31.8) | |
Mucopurulent | 13 (59.1) | 13 (59.1) | |
Purulent | 7 (31.8) | 2 (9.1) | |
Quality sputum culture | | | 0.093 |
No bacterial growth | 7 (31.8) | 9 (40.9) | |
Pseudomonas aeruginosa | 6 (27.3) | 2 (9.1) | |
Haemophilus influenzae | 4 (18.2) | 1 (4.5) | |
Other PPMs | 3 (13.6) | 5 (22.7) | |
No sample collected | 2 (9.1) | 5 (22.7) | |
FEV1% predicted | 58.1±22.9 | 64.6±21.1 | 0.336 |
FEV1 L | 1.6±0.8 | 1.5±0.4 | 0.762 |
Number of affected lobes# | | | 0.469 |
1 | 0 (0) | 3 (13.6) | |
2 | 10 (45.5) | 7 (31.8) | |
3 | 2 (9.1) | 3 (13.6) | |
4 | 7 (31.8) | 7 (31.8) | |
≥5 | 3 (13.6) | 2 (9.1) | |
SGRQ score units | 40.2±13.7 | 35.0±9.9 | 0.157 |
LCQ score units | 14.5±3.4 | 15.7±1.9 | 0.160 |
mMRC¶ | 1 (0–1.25) | 1 (1–1.25) | 0.511 |
6MWT m | 417.8±67 | 382.9±76.9 | 0.116 |
BSI# | | | 0.090 |
Mild | 2 (9.1) | 8 (36.4) | |
Moderate | 10 (45.5) | 6 (27.3) | |
Severe | 10 (45.5) | 8 (36.4) | |
FACED score# | | | 0.640 |
Mild | 11 (50) | 14 (63.6) | |
Moderate | 9 (40.9) | 7 (31.8) | |
Severe | 2 (9.1) | 1 (4.5) | |
Long-term antibiotic therapy# | | | 0.408 |
Inhaled antibiotic | 8 (36) | 6 (27) | |
Oral antibiotic | 4 (18) | 2 (9) | |
Oral corticosteroid therapy# | 1 (4.5) | 2 (9.1) | 1 |
Inhaled corticosteroid therapy | 16 (72.7) | 17 (77.3) | 0.728 |
Inhaled bronchodilator therapy | 16 (72.7) | 18 (81.8) | 0.360 |